Fewer models. Faster results.
We can do everything you might find in SEG II and III studies, but use fewer non-human primate models. This optimized study design can help you evaluate the functional consequences of mid to late gestational exposure. This analysis can be very insightful when assessing risk in monoclonal antibodies.